StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Equities research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Wednesday. The brokerage set a “hold” rating on the stock.

A number of other research firms have also weighed in on ONCT. HC Wainwright reduced their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Northland Securities reissued a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ:ONCT opened at $0.75 on Wednesday. The business has a fifty day moving average price of $1.34 and a 200-day moving average price of $4.74. The company has a market capitalization of $2.22 million, a PE ratio of -0.06 and a beta of 1.33. Oncternal Therapeutics has a 1-year low of $0.62 and a 1-year high of $13.14.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 16.05% of the stock is currently owned by institutional investors.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.